Background: To improve the therapeutic index of whole-brain radiation therapy (WBRT) in the treatment of brain metastases (BM) from breast cancer, we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population.
introduction
Breast cancer remains the second leading cause of central nervous system (CNS) metastases after nonsmall cell lung cancer (NSCLC). HER2-positive and triple-negative subtypes are especially and independently at increased risk of developing secondary brain lesions [1, 2] . The improved extracranial disease control rate with progress in systemic therapies explains the higher prevalence of brain metastases (BM), related to the natural history of breast cancer. A diagnosis-specific prognostic scoring system has been proposed for BMs according to the primary diagnosis and the cancer subtype. This approach helps to take into account the heterogeneity of this population, which is an essential point [3] . Surgical resection and radiosurgery are indicated in precise situations and only concern selected patients. In patients with large or multiple lesions (>4), wholebrain radiation therapy (WBRT) remains standard treatment but with limited efficacy, as the median overall survival is estimated to be <6 months [4] .
New therapeutic approaches are needed to optimize their management. However, some concomitant chemoradiotherapy regimens have been assessed in order to increase the therapeutic index of WBRT. Temozolomide (TMZ) is an oral alkylating agent that crosses the blood-brain barrier with documented radiosensitizing properties. Synergistic effects of radiation therapy and TMZ have been described in vitro and in vivo [5] . Main molecular mechanisms of this combination are based on enhanced capacity of double-stranded breaks in DNA causing failure in DNA repair systems. Several phase II studies have shown interesting brain response rates using WBRT plus concurrent TMZ and a positive impact of this combination on quality of life was reported [6] . It should be noted that all these clinical trials enrolled patients with BM from various solid cancers. The frequency of BM from breast cancer ranged from 10% to 68.1% depending on the study [7, 8] .
The aim of this study was to assess the efficacy and safety of WBRT with concomitant TMZ in treatment of BM especially from breast cancer.
patients and methods

study design
We developed a phase II, multicenter, randomized, open-label study. Three French Cancer Centers participated: Institut Curie (Paris, Saint Cloud), Institut Gustave Roussy (Villejuif), Centre François Baclesse (Caen). Eligible patients were randomly assigned to two arms: the WBRT arm or the WBRT plus concomitant TMZ arm. In accordance with the Helsinki Declaration, the project was approved by the Institut Curie Breast Cancer Study Group and the ethics committee of involved centers in September 2007. The Clinicaltrials.gov registration number was NCT00875355. An independent data safety monitoring board met every 6 months to ensure quality monitoring. All patients and gave their written informed consent to participate in the study.
patients
Eligible women were aged >18 years with ECOG Performance Status 0-2, and had at least one brain lesion from histologically documented primary breast cancer. BM were either unresectable or unsuitable for radiosurgery, or the patient refused surgery. Patients with leptomeningeal metastases or prior cranial irradiation including stereotactic radiosurgery were excluded. Adequate hematologic, renal and hepatic functions were required. Complete eligibility criteria are given in supplementary Table S1 , available at Annals of Oncology online.
Initial tumor histology and molecular subtype were recorded for each patient. For ER and PR status, a cutoff of 10% expression on immunochemistry analysis of tumor cells was applied. HER2 overexpression was defined as an immunohistochemistry score of 3 (+) or confirmed by FISH if 2+. All other IHC scores were defined as negative HER2 status.
treatment protocol
All patients received hypofractionated conformal WBRT to a dose of 30 Gy in ten equal daily fractions, given 5 days a week. WBRT was delivered using a linear accelerator, with two opposed photon beams. In the WBRT + TMZ arm, oral TMZ was administered continuously at a dose of 75 mg/m 2 /day (in a way similar to the prescribed dosage in the treatment of glioblastoma) [9] , on an empty stomach each morning during the brain irradiation period also on weekends for a total of 14 days. Preventive oral administration of sulfamethoxazole-trimethoprim was planned in this arm. No additional doses of TMZ were administered. Corticosteroids and antiepileptic drugs were prescribed at the lowest dosage, when necessary. Antiemetics were prescribed at the physician's discretion. Patients had not received chemotherapy during the 10 days preceding inclusion in the study protocol. The pretreatment assessment was carried out within 10 days of registration and included a complete clinical examination (medical history, physical examination) and laboratory tests (complete blood count with platelets, creatinine, liver function tests with bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase). A weekly medical consultation was required for each patient during the treatment period. Patients in the WBRT + TMZ arm were closely monitored for hematologic toxicity with twice weekly blood counts. Acute toxicities were reported using the NCI CTCAE v3 (Common Terminology Criteria for Adverse Events). Additional consultations were performed as necessary. If any ≥grade II hematotoxicity was observed, TMZ was immediately and definitely discontinued in the WBRT + TMZ arm.
assessment end points and follow-up
The primary end point of this study was the objective response rate (ORR) 6 weeks after the end of treatment, defined as complete or partial response on systematic gadolinium-enhanced brain magnetic resonance imaging (MRI) according to modified World Health Organization (WHO) criteria. MRI could be replaced by computed tomography brain imaging when necessary. The required brain MRI sequences were T1, T2 and gadolinium-enhanced T1 (axial slices). Additional gadolinium-enhanced T1 sequences in the coronal plane were used for 3D reconstruction. A measurable lesion was defined as a lesion with a diameter of at least 1 cm. Modified WHO criteria define four types of response: complete (100%), partial (50%-99%), stable disease and progression. A 2D method was used to measure brain lesions in this study. It included the two largest axial perpendicular diameters of each lesion, including its gadolinium enhancement but excluding peripheral edema. For each patient, measures could be recorded for up to five target lesions. All brain imaging examinations were reviewed by one blinded radiologist.
Secondary survival end points were overall progression-free survival (PFS) and overall survival (OS). PFS was measured from the date of diagnosis of BM to the date of progression. OS was measured from the date of diagnosis of BM to the date of death resulting from any cause. Toxic effects were also recorded.
After the first assessment at 6 weeks, a longer follow-up was planned for a maximum of 2 years [10] . Patients were reviewed for neurological symptoms and response (brain MRI) every 3 months for 6 months, and then every 6 months. The last examination was planned at the 2-year follow-up.
statistical analysis
This was a phase II randomized trial and each arm was analyzed independently. A centralized permuted-blocked randomization process was used. Within each treatment arm, a two-stage modified Fleming approach was proposed, allowing the study to be stopped only in the case of insufficient efficacy. The percentage defined in the null hypothesis was 30% and the expected percentage was 50%. Inclusion of 50 patients per arm were necessary to access the acceptable response rate of 50% with a power of 93% and with type I error α = 0.09.
Additional details on methodology are published as supplementary Material, available at Annals of Oncology online.
No comparison test was carried out between the two arms concerning the primary end point. Statistical analysis was based on intent-to-treat analysis. Patients who died or lost to follow-up were considered to be nonresponders.
The Kaplan-Meier method was used for survival analysis, survival curves were compared with a log-rank test. The Cox model was applied to evaluate the impact of adjusted prognostic factors in multivariate analysis. Survival rates and the hazard ratio (HR) associated with each prognostic factor were expressed with their confidence intervals (CIs). Statistical analyses were carried out using R software version 2.13.2 [11] . Table 1 . At the initial clinical examination, 37 patients (74%) in the WBRT arm and 44 patients in the WBRT + TMZ arm (88%) reported neurologic symptoms, mostly headaches (46% in the WBRT arm, 54% in the WBRT + TMZ arm).
Follow-up ended in November 2012. Median follow-up was 9.4 months (range: 1.0-68.1 months).
primary end point: objective response rate Three patients in the WBRT arm and ten patients in the WBRT + TMZ arm died as a result of tumor progression before the first assessment at 6 weeks. No treatment-related toxic effect was documented. Three other patients in the WBRT + TMZ arm did not complete the first assessment. Two patients were lost to follow-up and one patient discontinued because of tumor progression. Thirty-seven patients in the WBRT + TMZ arm and 47 patients in the WBRT arm were therefore assessable for the primary end point. The response rate was 36% (n = 18/50) (95% CI 22.9-50.8) in the WBRT arm versus 30% (n = 15/50) (95% CI 17.9-44.6) in the WBRT + TMZ arm on intent-to-treat analysis. No complete response was documented in either of the two arms. Results are summarized in Table 2 . Responses rates by treatment arm and by molecular subtype are provided in supplementary Table S2 , available at Annals of Oncology online.
survival
Median OS was 11.1 months (95% CI 8.3-15.3) and 9.4 months (95% CI 7.3-13.4) and median PFS was 7.4 months (95% CI 5.3-13.1) and 6.8 months (95% CI 4.6-8.6) in the WBRT arm and the WBRT + TMZ arm, respectively. These differences in PFS and OS were not statistically significant (Figure 1) .
For information purposes, HER2-positive cancers had the longest median OS: 16.1 and 20.2 months in the WBRT arm tary Tables S3 and S4 , available at Annals of Oncology online). More than 50% of patients died during the first 10 months. Eighteen patients were still alive after 24 months of follow-up (9 patients in each arm) (supplementary Figures S2 and S3 , available at Annals of Oncology online).
Multivariate analysis showed that HER2-positive breast cancer subtype treated with trastuzumab was positively associated with OS (HR = 0.47; 95% CI 0.23-0.95). A PS of 2 at study entry was strongly associated with poor OS and PFS (HR = 5.40; 95% CI 2.91-10.00, and HR = 3.73, 95% CI 2.12-6.58, respectively).
neurologic symptoms
At the 6-week assessment, 22 patients in the WBRT arm (44%) and 12 patients in the WBRT + TMZ arm (24%) experienced neurologic symptoms. Balance disorders were the most common symptoms (12 and 5 patients, respectively). No significant difference was observed between the two arms. An improvement in neurologic symptoms was reported by 31 patients in the WBRT arm (62%) and 27 patients in the WBRT + TMZ arm (54%).
safety
All patients were assessable for tolerability. No significant difference was observed between the two arms. Tolerability in the WBRT + TMZ arm was good, with mostly grade 1 or 2 toxicity. As expected, hematotoxicity was the most common category of adverse effects in this arm. Grade 3-4 lymphopenia was observed Table 3 .
discussion
To our knowledge, this is the first randomized trial to assess the efficacy of the WBRT-TMZ combination for BMs from breast cancer. No improvement in the control of BM was observed after 6 weeks of WBRT + TMZ in this population. TMZ is an alkylating agent with documented activity in the CNS [9] . Six phase II studies have assessed the TMZ and WBRT combination in patients with newly diagnosed BM from various primary cancers [6] [7] [8] [12] [13] [14] . Our study population was more homogeneous, as all patients had BM from breast cancer. It is difficult to compare the results of this study with those of previous studies due to the heterogeneity of study populations and treatment protocols. A protracted low-dose TMZ regimen was mostly used. None of the previously published studies demonstrated any efficacy on OS. Results of the first study by Antonadou et al. [7] , showing an ORR of 96% in the WBRT + TMZ arm versus 67% in the WBRT arm (P = 0.017), were not confirmed in lung cancer in phase III study by the same authors [15] . A 2-week treatment schedule with no additional TMZ was used in our study. Gamboa-Vignolle et al. showed promising results with this practical schedule in a population mostly presenting BM from breast cancer [8] . A dosedense regimen of TMZ was combined with WBRT at a dose of 30 Gy. The response rate was significantly better in the WBRT + TMZ arm: 78.6% versus 48.1% in the WBRT arm (P = 0.019), with a similar difference to that observed in the study by Antonadou et al. [7] . This response rate was reflected by improved PFS: 11.8 months versus 5.6 months (P = 0.005), but with a small sample size.
This study presents a number of limitations. No systematic quality of life and neurocognitive assessment was carried out in this phase II exploratory study. The statistical power of the analysis was also decreased by the high proportion of deaths and patients lost to follow-up before the first radiologic assessment. Several explanations can be proposed for our results. Chemotherapy is active but has limited efficacy on BM due to poor diffusion across the blood-brain barrier [16] . There is no evidence of the efficacy of TMZ as single-agent therapy in advanced breast cancer with BM [17, 18] . Although there were some long-term survivors in our study, the radiosensitizing effect of TMZ may be effective but not sufficient to achieve a long-term satisfactory clinical outcome. When the study was designed in 2007, limited information was available on the role of O 6 -methylguanine methyltransferase (MGMT)-mediated chemoresistance [19] and MGMT expression analysis was not carried out in this study.
Several approaches designed to improve the efficacy and safety of WBRT are currently under investigation. Molecular subtype is a prerequisite for personalized treatment of advanced breast cancer. Two phase II studies are assessing the efficacy of WBRT combined with two anti-HER2 agents, trastuzumab (NCT01363986) and lapatinib (NCT01622868), respectively. Data are still lacking for TNBC. Advances with molecular analysis of breast cancer BM, in comparison with primary breast cancer, could provide new therapeutic targets [20] .
conclusion BMs, a cause of significant morbidity and poor prognosis, remain a turning point in the cancer process. The combination of WBRT plus TMZ did not improve local control of BMs from breast cancer in this study. Based on these findings, this combination cannot be recommended. Further investigations are needed to improve the management of these patients. 
